IDWeek 2017
AWG Member Company Participation at IDWeek 2017
Thirteen AWG member companies presented data from their clinical and research programs at IDWeek 2017 taking which took place in San Diego from October 4 – 8, 2017. In addition to 59 poster presentations, representatives from AWG member companies participated in various panels and symposiums addressing the state of the antimicrobial development pipeline.
IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
Wednesday, October 4th
Affiliated Event
Time: 7:00 AM – 8:00 AM
Room: 09
T2Sepsis Solution: The Impact of Direct from Whole Blood Diagnostics on the Management of Bloodstream Infections (T2Candida and the T2Bacteria RUO Panel) https://idsa.confex.com/idsa/2017/webprogram/Session9585.html
- T2 Biosystems
Thursday, October 5th
Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD
HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens
Iterum Therapeutics:
- 400. Prevalence of Extended Spectrum Beta-Lactamase (ESBL) and Quinolone Non-susceptible (QNS) Enterobacteriaceae in Inpatient and Outpatient Settings in the USA from 2011-2016
Emerging Resistance – Epidemiology and Mechanisms
Melinta Therapeutics:
- 331. Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials
Theravance Biopharma:
- 333. Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens
Clinical: Bone and Joint Infection
Theravance Biopharma:
- 194. Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
Fungus Among Us: Basic Science
Viamet Pharmaceuticals:
- 274. VT-1598 Inhibits the in vitro Growth of Mucosal Candida Isolates and Protects Against Oropharyngeal Candidiasis in IL-17 Deficient Mice
Symposium
Time: 2:00 PM – 3:00 PM
Room: 20ABCD
New Antibiotics: What’s in the Pipeline https://idsa.confex.com/idsa/2017/webprogram/Session8957.html
Melinta Therapeutics:
Time: 2:00 PM
- 857. Delafloxacin – Sue K. Cammarata, MD
Zavante Therapeutics:
Time: 2:09 PM
- 858. Fosfomycin for Injection – Evelyn J. Ellis-Grosse, Ph.D.
Paratek Pharmaceuticals:
Time: 2:36 PM
- 862. Omadacycline, the First Aminomethylcycline – Paul McGovern, MD
Nabriva Therapeutics:
Time: 2:45 PM
- 862. Lefamulin – Steven P. Gelone, PharmD
Friday, October 6th
Meet the Professor Session
Time: 7:00 AM – 8:15 AM
Room: 06DE
Pipeline 2.0 https://idsa.confex.com/idsa/2017/webprogram/Session9191.html
AWG Panelists:
- Sue K. Cammarata, MD – Melinta Therapeutics
- Evelyn J. Ellis-Grosse, Ph.D. – Zavante Therapeutics, Inc.
- Paul McGovern, MD – Paratek Pharmaceuticals
- Steven P. Gelone, PharmD – Nabriva Therapeutics AG
Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD
Adult Immunization – Miscellaneous
Arsanis:
- 1025. Serum and lung pharmacokinetics of ASN100, a monoclonal antibody combination for the prevention and treatment of Staphylococcus aureus pneumonia
Preclinical Study with New Antibiotics and Antifungals
Amplyx Pharmaceuticals:
- 1510. Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
- 1513. Absorption, Distribution, and Excretion of 14C‑APX001 after Single-Dose Administration to Rats and Monkeys
- 1521. APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
- 1522. Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
- 1529. Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
Cidara Therapeutics:
- 1518. Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis
- 1528. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
- 1533. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model
Melinta Therapeutics:
- 1532. Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
Nabriva Therapeutics:
- 1509. Efficacy of Lefamulin Against Staphylococcus aureus – Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model
Paratek Pharmaceuticals:
- 1531.In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model
Scynexis:
- 1508. SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
- 1511. SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of InvasiveAspergillosis
Zavante Therapeutics:
- 1517. ZTI-01 Treatment Improves Survival of Animals Infected with Multidrug Resistant Pseudomonas aeruginosa
- 1523. Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM)
Expanded Spectrum – New Antimicrobial Susceptibility Testing
Contrafect Corporation:
- 1212. Lysin CF-301 DemonstratesIn Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
- 1213. Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA and Europe
Melinta Therapeutics:
- 1208.In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Community-Acquired Bacterial Respiratory Tract Infection Isolates (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program
- 1222.Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe During 2014-2016 as Part of a Global Surveillance Program
Nabriva Therapeutics:
- 1218. In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia
- 1220. In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
Paratek Pharmaceuticals:
- 1223. In Vitro Activity of Omadacycline and Comparator Compounds against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
Scynexis:
- 1206. Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
Zavante Therapeutics:
- 1224.In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
Saturday, October 7th
Oral Abstract Session
Time: 8:30 AM – 10:00 AM
Room: 01AB
The Fungus Among-us – Clinical Advances
T2 Biosystems:
- 1774. Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel
Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD
Clinical Study with New Antibiotics and Antifungals
Arsanis:
- 1844. Prevention of Lung Pathology and Mortality in Rabbit Staphylococcus aureus Pneumonia with Cytotoxin-Neutralizing Monoclonal IgGs that Penetrate Epithelial Lining Fluid
- 1849. Population Pharmacokinetic Model for Intravenous ASN100 in Healthy Subjects
- https://idsa.confex.com/idsa/2017/webprogram/Paper64041.html
Amplyx Pharmaceuticals:
- 1840. First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
- 1860. Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
Iterum Therapeutics:
- 1839. A Phase 1 Study to Assess the Pharmacokinetics of Sulopenem Etzadroxil (PF-03709270)
Melinta Therapeutics:
- 1851. Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Support Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 1854. Impact of Delafloxacin (DLX) and Vancomycin/Aztreonam (VAN/AZ) on Resolution of Signs and Symptoms of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 1856. Outcomes with IV/oral Delafloxacin (DLX) Compared to Vancomycin/Aztreonam (VAN/AZ) in Treatment of Patients (pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-negative (GN) Pathogens
- 1857. Outcomes with IV/oral Delafloxacin (DLX) Compared to Vancomycin/Aztreonam (VAN/AZ) in Treatment of Patients (pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-positive (GP) Pathogens
- 1858. Comparison of Safety Profile of Delafloxacin (DLX) versus Vancomycin/Aztreonam (VAN/AZ) in the Treatment of Patients (Pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Integrated Safety Findings from Two Phase III Studies
Paratek Pharmaceuticals:
- 1834. Efficacy and Safety of Omadacycline in Chronic Kidney Disease (CKD) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial
- 1838. Efficacy and Safety of Omadacycline in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and High Body Mass Index or Type 2 Diabetes: A Subgroup Analysis from the OASIS Trial
- 1850. A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration
- 1875. Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumoniae (CABP) trial: The OPTIC study
- 1883. A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)
- 1885. Efficacy and Safety of Omadacycline in Intravenous Drug Using (IVDU) and Hepatitis C-Positive (HCV+) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial
- 1886. Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies
Theravance Biopharma:
- 1861. Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Preliminary results from the Telavancin Observational Use Registry (TOUR™)
Zavante Therapeutics:
- 1830. Phenotypic Antibiotic Resistance in ZEUS: A Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 versus Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis (AP)
- 1833. Per Pathogen Outcomes from the ZEUS study, a Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 (fosfomycin for injection) versus Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis (AP)
- 1837. Safety Results from the ZEUS Study: Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) who Received
- 1845. Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)
- 1848. Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)
Diagnostics – Mycology
T2 Biosystems:
- 2066. Utilization of the T2Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
- 2067. Relationship of T2Candida Panel to Disease Severity, Mortality and Time to Therapy in Patients with Candidemia
- 2069. Automated Detection of Candida auris Direct from Whole Blood by T2MR
- 2081. Does a Negative Rapid Diagnostic Test for Detection of Candida Bloodstream Infection Lead to Less Antifungal Use?
Stewardship: Impact of Diagnostics
T2 Biosystems:
- 2137. Influence of T2Candida Testing for Rapid Diagnosis of Candida Infections on Antifungal Stewardship Efforts at a Large Academic Medical Center: A Retrospective, Single-Center Study